MRNA Moderna
- Official Name: MODERNA, INC.
- Headquarters: 325 BINNEY STREET, Cambridge, MA, 02142 US
- CEO: Stephane Bancel
- Website: modernatx.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 8.182 | 6.060 - (2.122) | ||
| 2025-07-15 | 1R | Lost by 1.908 | (2.795) - (0.887) | ||
| 2025-07-16 | 1R | Won by 0.668 | 1.177 - 0.509 | ||
| 2025-07-21 | 2 | Lost by 6.337 | (5.332) - 1.005 | ||
| 2025-07-28 | 3 | Won by 6.555 | 7.684 - 1.129 | ||
| 2025-08-04 | 4 | Lost by 16.156 | (13.626) - 2.530 | ||
| 2025-08-07 | 1R | Lost by 1.697 | (0.718) - 0.979 | ||
| 2025-08-11 | 5 | Lost by 7.425 | (7.884) - (0.459) | ||
| 2025-08-18 | 6 | Won by 6.188 | 9.102 - 2.914 | ||
| 2025-08-25 | 7 | Lost by 7.167 | (7.798) - (0.631) | ||
| 2025-09-01 | 8 | Lost by 8.329 | (4.456) - 3.873 | ||
| 2025-09-08 | 9 | Lost by 0.743 | 2.875 - 3.618 | ||
| 2025-09-15 | 10 | Lost by 4.155 | (3.435) - 0.720 | ||
| 2025-09-22 | 11 | Won by 8.897 TOTW | 9.953 - 1.056 | ||
| 2025-09-29 | 12 | Lost by 4.268 | (4.333) - (0.065) | ||
| 2025-10-06 | 13 | Won by 6.939 TOTW | 9.061 - 2.122 | ||
| 2025-10-13 | 14 | Lost by 0.924 | (3.000) - (2.076) | ||
| 2025-10-20 | 15 | Won by 2.073 | 2.073 - 0.000 |
Latest News

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase ...
Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $137
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $120 to $137.

Top S&P500 movers in Wednesday's session
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...

Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug
Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.

Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug
Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.

What the interest rate danger zone means for your money
Gabelli Funds Portfolio Manager Justin Bergner and NYSE Senior Market Strategist Michael Reinking break down how the AI boom, rising interest rates, a...

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?

10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transac...

Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), ann...

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA h...

Tuesday's pre-market session: top gainers and losers in the S&P500 index
Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics.

Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a. ET...

ValuEngine Weekly Commentary With Strategy Notes
U.S. equity markets were mixed this week, with broader gains across value, defensive, and cyclical sectors offset by weakness in technology and the NA...

Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
Is bigger always better? Not necessarily.

S&P Hits All-Time Highs, AI Trade Does All The Work
From June we saw money rotate out of tech into reflationary sectors, also software, explains Amrita Roy and Uttam Dey. Now, money is moving back into ...

Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer Vaccines
Key TakeawaysModerna stock surged 14. 2% on October 9 after reports of an NIH-backed initiative to accelerate cancer vaccine development.

Where Could Moderna's Next Growth Come From?
Moderna (MRNA) stock has returned 621% over the past twelve months, easily outpacing the S&P 500's 17.0% return. Yet the company's sales...

Here's Why Moderna (MRNA) Fell More Than Broader Market
In the closing of the recent trading day, Moderna (MRNA) stood at $213.63, denoting a -5.05% move from the preceding trading day.

Discover which S&P500 stocks are making waves on Monday.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.

Moderna stock surges more than 600% in 2026
The vaccine maker's stock gained 18% last week after a report on a planned NIH cancer vaccine initiative and its addition to the Nasdaq-100

Merck (MRK) Could Be 7% Below Fair Value On Phase III Cancer Vaccine Results
Merck (MRK) is back in focus after reporting positive Phase III results from its personalized mRNA cancer vaccine program with Moderna, a development ...

Tempus AI Expands Strategic Collaborations to Drive Future Growth
TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenu...

Moderna’s (MRNA) Cancer Vaccine Breakthrough Drives Sharp Stock Rally
Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategyâ...

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research fundi...

Tech slumps as oil prices rise, focus turns to earnings season kickoff: AlphaCheck
Stocks were little changed on Monday ahead of a big earnings week.

Dr. Scott Gottlieb on push to fast-track cancer vaccines, flu season and AI integration in hospitals
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the public-private push to accelerate cancer vaccine development, h...

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
Forget the "Magnificent Seven" in favor of the "Tremendous Three"?

Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’
Palantir CTO Shyam Sankar calls AI doomsday predictions theological, while warning that extreme optimism amounts to ‘mass psychosis,'

Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.

Why Did MRNA, HUM, LITE Stocks Surge To 52-Week Highs Last Week?
The rallies highlighted growth opportunities across biotechnology, health insurance and optical technology.

Moderna (MRNA) Is Up 18.4% After Cancer Vaccine Milestone And Nasdaq-100 Return Has The Bull Case Changed?
Moderna, Inc. was added back to the Nasdaq-100 index and earlier announced that former manufacturing leader Juan Andres would return as Chief Operatin...

Moderna (MRNA) Stock Looks Expensive Following Its 7x One Year Run
Moderna has surged back into the spotlight after a powerful share price run, which puts a fresh focus on whether the current US$225.00 level can be su...

Moderna (MRNA) Stock Sees Modest Fair Value Lift After Cancer Vaccine Analyst Revisions
Moderna’s updated modelling now points to a slightly higher fair value estimate, with the figure moving from US$119.56 to US$122.67 per share. That ...

Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
After a few years of stagnation, this stock is soaring.

A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
Moderna stock is up 663% in 2026, beating AI names for the S&P 500 lead. Full cancer vaccine data arrives October 24.